NEW YORK, Nov. 25, 2021 /PRNewswire/ -- The "Dravet Syndrome Treatment Market - Competitive Analysis, Trends, Drivers, Challenges, and Five Force Analysis" report has been added to Technavio's offering. The dravet syndrome treatment market size is expected to increase by USD 444.54 million, at a CAGR of  9.41% from 2020 to 2025. 39% of the market's growth will originate from North America. The US and Canada are the key markets for the Dravet syndrome treatment market in North America.  

For more insights on Dravet Syndrome Treatment Market - Download a free sample now!

Market Dynamics

The market is driven by factors such as the rising strategic alliances, increasing new product launches, and the growth in special regulatory designations. However, low awareness is hindering market growth.

Company Profiles

The dravet syndrome treatment market is fragmented and the vendors are deploying various organic and inorganic growth strategies to compete in the market. Some of the companies covered in this report are AbbVie Inc., BIOCODEX SAS, Cadila Healthcare Ltd., Epygenix Therapeutics Inc., H. Lundbeck AS, PTC Therapeutics Inc., Supernus Pharmaceuticals Inc., Takeda Pharmaceutical Co. Ltd., and Zogenix Inc., etc. 

Key Offerings of Few Companies -

• AbbVie Inc. - The company offers Stiripentol under the brand name of Diacomit which is used for the treatment of Dravet syndrome.
• BIOCODEX SAS -  The company provides Brivaracetam tablets which help to cure Dravet syndrome.
• Cadila Healthcare Ltd - The company provides medicines such as EPX 100, 101, 102, 103, and others for the treatment of Dravet syndrome.

Competitive Analysis

The competitive scenario provided in the Dravet syndrome treatment market report analyzes, evaluates, and positions companies based on various performance indicators. Some of the factors considered for this analysis include the financial performance of companies over the past few years, growth strategies, product innovations, new product launches, investments, growth in market share, etc.

Market Segmentation

• By Product, the market is classified into SGDs, TGDs, and FGDs.The dravet syndrome treatment market share growth by the SGDs segment has been significant
• By Geography, the market is classified as North America, Europe, Asia, and ROW. North America will have the largest share of the market.

Related Reports -
Sjogren's Syndrome Therapeutics Market -The Sjogren's syndrome therapeutics market size has the potential to grow by USD 287.68 million during 2021-2025, and the market's growth momentum will accelerate at a CAGR of 4.05%. Download a free sample now!

Dry Eye Syndrome Drugs Market -The dry eye syndrome drugs market size has the potential to grow by USD 2.08 billion during 2021-2025, and the market's growth momentum will accelerate at a CAGR of 6.81%. Download a free sample now!

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

View original content to download multimedia:https://www.prnewswire.com/news-releases/usd-444-54-mn-growth-for-dravet-syndrome-treatment-market-by-2025-evolving-opportunities-with-cadila-healthcare-ltd--epygenix-therapeutics-inc17000-technavio-reports-301431543.html

SOURCE Technavio